CLINICAL TRIALS PROFILE FOR OPZELURA
✉ Email this page to a colleague
All Clinical Trials for OPZELURA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05750823 ↗ | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | Not yet recruiting | Incyte Corporation | Phase 2 | 2023-03-06 | An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas identified for treatment at baseline regardless of whether the area begins to improve or fully repigment. |
| NCT05764161 ↗ | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Not yet recruiting | Incyte Corporation | Phase 3 | 2023-04-13 | The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OPZELURA
Condition Name
Clinical Trial Progress for OPZELURA
Clinical Trial Phase
Clinical Trial Sponsors for OPZELURA
Sponsor Name
